This "research announcement" is of zero commercial...

This "research announcement" is of zero commercial value.

It's a capital market storytelling fairytale.

BOD do not own any IP over the underlying product as it's a white labelled product from Linnea in Switzerland. It's generic CBD that any LP can go, buy and sell today.

The research doesn't demonstrate superiority of their CBD over any product so is of zero use.

Why BOD are purely interested in any cheap tactic to elevate their stock price is beyond me.

Craig and Jo - stop with the useless "toilet paper" clinical trials.

1. Create a novel product where you own the IP.

2. Demonstrate superiority over current innovators/ existing therapy through sound clinical trials not underpowered,
observational ones.

3. Pursue appropriate registration through regulatory channels (FDA/ EMA/ TGA)

4. Commercialise the drug properly through valid channels.

All this rubbish about hopeless trials with non-registrable products is storytelling for your stock price.

When will BOD and ZLD stop peddling this trash.